NEXSPIKE is Moderna’s third product to receive a positive CHMP opinion alongside Spikevax (COVID-19 Vaccine, mRNA) and ...

Moderna Inc. (NASDAQ:MRNA) is one of the high short interest stocks to buy right now. On November 20, Moderna announced that ...

Moderna is seeking to enhance some of its drugs with Nanexa’s technology as the biologics sector moves to less frequent ...

Moderna has tapped Swedish long-acting drug formulation company Nanexa to improve the delivery of up to five injectable ...

Moderna's narrative is shifting as analysts modestly trim their fair value from $37.32 to $35.78 per share and nudge the ...

Moderna on Monday said that the European Medicines Agency's Committee for Medicinal Products for Human Use recommended the marketing authorization of mNexspike, a new Covid-19 vaccine. The committee's ...

Moderna (NASDAQ: MRNA) extended gains for the seventh consecutive trading session, with the stock closing 2.14% higher at $29 ...

An expert panel of the EU drug regulator, the European Medicines Agency (EMA), endorsed seven new medicines for approval this ...

The decision applies to adolescents and adults and aligns with earlier US authorization for higher-risk groups.

Good things could be on the horizon when a stock surpasses the 20-day simple moving average. How should investors react?

Ever since the COVID-19 pandemic began to ease, Moderna has weathered a sharp revenue downturn. But a new FDA approval shows that the company's scientific engine is no one trick pony. Moderna's ...

Moderna (NASDAQ: MRNA) provided updates on the manufacturing of its Covid-19 vaccine, noting that it was increasing the baseline production estimate for this year to 600 million doses, 100 million ...